Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
about
Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphomaTreatment of primary Sjögren syndrome.Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.Nodal involvement by marginal zone B-cell lymphoma harboring t(14;22)(q32;q11) involving immunoglobulin heavy chain and light chain lambda as the sole karyotypically recognizable abnormality in a patient with systemic lupus erythematosus.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Biological therapies in primary Sjögren's syndrome.Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management.Safety of treatments for primary Sjögren's syndrome.B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.Current and prospective treatment options for Sjögren's syndrome.Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.Topical and systemic medications for the treatment of primary Sjögren's syndrome.Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome.Sjögren syndrome
P2860
Q24644580-915F2B47-713A-4F8A-A1B9-8B61F941B1ABQ30249011-9B3BD571-E289-42D1-81CE-2C14FA2ECD24Q33372523-9109CE1C-E8EB-448E-8195-BD8843EE3986Q34121629-14A6DE55-3B2F-48D8-A490-2F9ECEBD47D4Q36171750-353BB1D1-CA9D-40F6-8CFC-45B14CC737C5Q37860347-3E2C485C-8B51-4B30-861C-1EF3027548DBQ37884384-81329C38-C62E-4390-AB1E-1F9647C1F439Q38260354-EF33B6E7-55D0-47F4-834C-85E803E3B21DQ38711144-50FA11CB-88AD-4EA3-BD8C-4D3C5DF1BBFEQ38813104-1DC329B2-BD87-4205-99F2-EB37E4A5CB09Q40076686-7870CE86-2897-4CB7-A442-AAB5357C9319Q40383414-6E3DB3D6-B27D-4AEC-AB5E-8CE57062E7FCQ42921901-B35289E3-EF83-4ECF-9160-7A5B7445A419Q44498935-FC2807C3-208A-434D-87F8-771996633517Q55446969-5404A5B0-BEDF-49F6-A2E6-155A2360979DQ55970262-E4AEAD6A-59D4-4F06-AE0A-150D97FC8A7D
P2860
Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@ast
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@en
type
label
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@ast
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@en
prefLabel
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@ast
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@en
P2093
P2860
P356
P1476
Long term remission of Sjögren ...... cin, vincristine, prednisone).
@en
P2093
Giannouli S
Moutsopoulos HM
Tzioufas AG
Voulgarelis M
P2860
P304
P356
10.1136/ARD.2005.046193
P407
P577
2005-12-01T00:00:00Z